Hard to Treat Diseases Inc. (HTDS) Research

Hard to Treat Diseases Inc. (HTDS), founded in 2009 and headquartered in Shenzhen, China, is a pharmaceutical firm engaged in the development, manufacturing, and global export of biopharmaceutical products and vaccines. The company's extensive portfolio includes a range of biological agents such as reteplase (rPA), mycobacterium vaccae, acutobin urinary kallidinogenase, ulinastatin, and cerebroprotein hydrolysate for injection. HTDS also provides various chemical pharmaceuticals, including cobratide injection, entecavir capsules, HES, dasatinib tablets, thymosin a1 for injection, imipenem and cilastatin sodium for injection, and meropenem for injection. Additionally, it supplies critical vaccines for rabies, ACYW135 meningococcal disease, influenza, Hepatitis A, and varicella. HTDS distributes its offerings through a sales network primarily focused on markets in South Asia, Southeast Asia, Central and South America, and the Middle East.

Open Hard to Treat Diseases Inc. (HTDS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.